Format
Sort by
Items per page

Send to

Choose Destination

Best matches for antihypertensive agents AND diuretics AND kidney failure AND pharmacotherapy:

Search results

Items: 1 to 20 of 870

1.

A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trial.

Hayer MK, Edwards NC, Slinn G, Moody WE, Steeds RP, Ferro CJ, Price AM, Andujar C, Dutton M, Webster R, Webb DJ, Semple S, MacIntyre I, Melville V, Wilkinson IB, Hiemstra TF, Wheeler DC, Herrey A, Grant M, Mehta S, Ives N, Townend JN.

Am Heart J. 2017 Sep;191:37-46. doi: 10.1016/j.ahj.2017.05.008. Epub 2017 May 24.

PMID:
28888268
2.

Treatment of uncomplicated hypertension is associated with a reduction in cardiovascular mortality: a Korean national cohort study.

Lee CJ, Hwang J, Oh J, Lee SH, Kang SM, Choi D, Kim HC, Park S.

J Hypertens. 2017 May;35 Suppl 1:S41-S49. doi: 10.1097/HJH.0000000000001331.

PMID:
28350620
3.

Salt supplementation ameliorates developmental kidney defects in COX-2<sup>-/-</sup> mice.

Slattery P, Frölich S, Goren I, Nüsing RM.

Am J Physiol Renal Physiol. 2017 Jun 1;312(6):F1044-F1055. doi: 10.1152/ajprenal.00565.2016. Epub 2017 Mar 8.

PMID:
28274925
4.

Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial.

Moes AD, Hesselink DA, van den Meiracker AH, Zietse R, Hoorn EJ.

Am J Kidney Dis. 2017 Jun;69(6):796-804. doi: 10.1053/j.ajkd.2016.12.017. Epub 2017 Mar 1.

PMID:
28259499
5.

Uncontrolled hypertension among patients managed in primary healthcare facilities in Kinshasa, Democratic Republic of the Congo.

Kika TM, Lepira FB, Kayembe PK, Makulo JR, Sumaili EK, Kintoki EV, M'Buyamba-Kabangu JR.

Cardiovasc J Afr. 2016 Nov/Dec;27(6):361-366. doi: 10.5830/CVJA-2016-036.

6.

Hypertension control and care at Mulago Hospital ambulatory clinic, Kampala-Uganda.

Ssinabulya I, Nabunnya Y, Kiggundu B, Musoke C, Mungoma M, Kayima J.

BMC Res Notes. 2016 Nov 17;9(1):487.

7.

Empagliflozin (Jardiance). Type 2 diabetes: no rush to use this drug.

[No authors listed]

Prescrire Int. 2016 Jun;25(172):145-8. Review.

PMID:
27486640
8.

[NEPHROPROTECTIVE PROPERTIES OF 5-HT3 RECEPTOR BLOCKER RU-63 IN EXPERIMENTAL ACUTE RENAL FAILURE UNDER HYPERGRAVITY CONDITIONS].

Zaitseva EN, Dubishchev AV, Yakovlev DS, Anisimova VA.

Eksp Klin Farmakol. 2016;79(3):18-26. Russian.

PMID:
27455574
9.

Addition of hydrochlorothiazide to angiotensin receptor blocker therapy can achieve a lower sodium balance with no acceleration of intrarenal renin angiotensin system in patients with chronic kidney disease.

Fuwa D, Fukuda M, Ogiyama Y, Sato R, Mizuno M, Miura T, Abe-Dohmae S, Michikawa M, Kobori H, Ohte N.

J Renin Angiotensin Aldosterone Syst. 2016 Jun 9;17(2):1470320316652032. doi: 10.1177/1470320316652032. Print 2016 Apr-Jun.

10.

Update in Hypertension Therapy.

Mankin LA.

Med Clin North Am. 2016 Jul;100(4):665-93. doi: 10.1016/j.mcna.2016.03.005. Review.

PMID:
27235610
11.

Resistant Hypertension and Chronic Kidney Disease: a Dangerous Liaison.

Wolley MJ, Stowasser M.

Curr Hypertens Rep. 2016 Apr;18(5):36. doi: 10.1007/s11906-016-0641-x. Review.

PMID:
27072829
12.

Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure.

Sica DA.

Methodist Debakey Cardiovasc J. 2015 Oct-Dec;11(4):235-9. doi: 10.14797/mdcj-11-4-235. Review.

13.

Recent Developments and Controversies in the Treatment of Resistant Hypertension.

Kühl C, Frey N, Frank D.

Exp Clin Endocrinol Diabetes. 2016 Mar;124(3):178-86. doi: 10.1055/s-0042-100912. Epub 2016 Mar 23. Review.

PMID:
27008634
14.

Loop diuretics are most appropriate for hypertension treatment in chronic kidney disease.

Elliott WJ, Jurca S.

J Am Soc Hypertens. 2016 Apr;10(4):285-7. doi: 10.1016/j.jash.2016.02.007. Epub 2016 Feb 26. No abstract available.

PMID:
26993218
15.

Thiazides are useful agents in CKD.

Sinha AD, Agarwal R.

J Am Soc Hypertens. 2016 Apr;10(4):288-9. doi: 10.1016/j.jash.2016.02.006. Epub 2016 Feb 26. No abstract available.

PMID:
26987648
16.

Is there a preferred diuretic class for patients with renal impairment and hypertension?

Izzo JL Jr, Tobe SW.

J Am Soc Hypertens. 2016 Apr;10(4):282-4. doi: 10.1016/j.jash.2016.02.008. Epub 2016 Feb 23.

PMID:
26979914
17.

Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT.

Whittle J, Lynch AI, Tanner RM, Simpson LM, Davis BR, Rahman M, Whelton PK, Oparil S, Muntner P.

Clin J Am Soc Nephrol. 2016 Mar 7;11(3):471-80. doi: 10.2215/CJN.04660415. Epub 2016 Feb 18.

18.

Aichi cohort study of the prognosis in patients newly initiated into dialysis (AICOPP): baseline characteristics and trends observed in diabetic nephropathy.

Hishida M, Tamai H, Morinaga T, Maekawa M, Aoki T, Tomida H, Komatsu S, Kamiya T, Maruyama S, Matsuo S, Inaguma D.

Clin Exp Nephrol. 2016 Oct;20(5):795-807. Epub 2016 Feb 23.

PMID:
26905064
19.

New therapies for arterial hypertension.

Pagliaro B, Santolamazza C, Rubattu S, Volpe M.

Panminerva Med. 2016 Mar;58(1):34-47. Epub 2016 Jan 5. Review.

PMID:
26730462
20.

Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.

Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K.

Lancet. 2016 Mar 5;387(10022):957-967. doi: 10.1016/S0140-6736(15)01225-8. Epub 2015 Dec 24. Review.

PMID:
26724178

Supplemental Content

Loading ...
Support Center